Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 6/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 6/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23723154 | 1.00 | ITGB3 (0.39) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL17924757 | 0.98 | ITGB3 (0.38) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL16749338 | 0.81 | — | — | |
| SCHEMBL18721171 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL17924744 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL17924726 | 0.79 | — | — | |
| SCHEMBL18826932 | 0.78 | ALOX5 (0.34) | CYP2C9MEN1KMT2A | |
| SCHEMBL21111223 | 0.77 | PTGIR (0.33) | — | |
| SCHEMBL17933284 | 0.77 | LMNA (0.37) | CYP2C9MEN1KMT2A | |
| SCHEMBL23723008 | 0.76 | ITGB3 (0.39) | ITGB3ITGB2ITGB1ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024038128-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| EP-3071564-B1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-9498479-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-9498479-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-07-21 | — | — | US | disclosed |
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-07-21 | — | — | US | disclosed |
| WO-2015074546-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-05-28 | — | — | WO | disclosed |
| CN-103153993-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | ITGB3 2718/4885ITGB2 3086/4885ITGB1 3192/4885 |
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | ITGB3 4871/4885ITGB2 4855/4885ITGB1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.